These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 12372228)

  • 1. [Functionality as a goal in the treatment of schizophrenia].
    García B;
    Actas Esp Psiquiatr; 2002; 30(5):312-25. PubMed ID: 12372228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive effects of conventional and atypical antipsychotics in schizophrenia.
    Sharma T
    Br J Psychiatry Suppl; 1999; (38):44-51. PubMed ID: 10884899
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
    Kasper S
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.
    Harvey PD; Green MF; Keefe RS; Velligan DI
    J Clin Psychiatry; 2004 Mar; 65(3):361-72. PubMed ID: 15096076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Social cognition and atypical antipsychotic agents in the treatment of persons with schizophrenia: preliminary data from a naturalistic study].
    Mazza M; Tozzini C; Giosué P; De Risio A; Palmucci M; Roncone R; Casacchia M
    Clin Ter; 2003; 154(2):79-83. PubMed ID: 12856365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Typical and atypical antipsychotics: Is there a difference in their influence on neurocognition?].
    Faber G; van Gool AR; Smid HG; Wiersma D; van den Bosch RJ
    Tijdschr Psychiatr; 2011; 53(2):107-17. PubMed ID: 21319067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating clinical trial data: outcome measures.
    Conley RR
    J Clin Psychiatry; 2001; 62 Suppl 9():23-6; discussion 27-8. PubMed ID: 11379827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic treatment in schizophrenia: the role of computerized neuropsychological assessment.
    Kertzman S; Reznik I; Grinspan H; Weizman A; Kotler M
    Isr J Psychiatry Relat Sci; 2008; 45(2):114-20. PubMed ID: 18982837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of cognitive dysfunction in schizophrenia.
    Peuskens J; Demily C; Thibaut F
    Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?
    Motlová L; Spaniel F; Höschl C; Balon R
    Ann Clin Psychiatry; 2007; 19(2):133-43. PubMed ID: 17612853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
    Chue P
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function.
    Swerdlow NR; Light GA; Cadenhead KS; Sprock J; Hsieh MH; Braff DL
    Arch Gen Psychiatry; 2006 Dec; 63(12):1325-35. PubMed ID: 17146007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 15. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
    Naber D; Lambert M; Karow A
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics.
    Tyson PJ; Laws KR; Flowers KA; Tyson A; Mortimer AM
    Psychiatry Clin Neurosci; 2006 Aug; 60(4):473-9. PubMed ID: 16884450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics.
    Kilian R; Dietrich S; Toumi M; Angermeyer MC
    Acta Psychiatr Scand; 2004 Aug; 110(2):108-18. PubMed ID: 15233711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.